Cargando…

Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts

SIMPLE SUMMARY: GC1118 is a novel anti-EGFR monoclonal antibody with a distinct mode of epitope binding. Its therapeutic efficacy has been validated in preclinical studies of several cancers. We evaluated the anti-tumor efficacy of GC1118 against glioblastoma (GBM) using patient-derived xenografts (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Kyoungmin, Koo, Harim, Kim, Yejin, Kim, Donggeon, Son, Eunju, Yang, Heekyoung, Lim, Yangmi, Hur, Minkyu, Lee, Hye Won, Choi, Seung Won, Nam, Do-Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693807/ https://www.ncbi.nlm.nih.gov/pubmed/33142709 http://dx.doi.org/10.3390/cancers12113210

Ejemplares similares

Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts
por: Lee, Hye Won, et al.
Publicado: (2019)

A multicenter, phase II trial of GC1118, a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification
por: Choi, Seung Won, et al.
Publicado: (2023)

A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors
por: Chung, Tae Kyu, et al.
Publicado: (2021)

Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models
por: Lee, Mijeong, et al.
Publicado: (2019)

EGFR Amplification and Glioblastoma Stem-Like Cells
por: Liffers, Katrin, et al.
Publicado: (2015)

Uncertainty quantification in the radiogenomics modeling of EGFR amplification in glioblastoma
por: Hu, Leland S., et al.
Publicado: (2021)

A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors
por: Oh, Do‐Youn, et al.
Publicado: (2019)

Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy
por: Kim, Dong Geon, et al.
Publicado: (2016)

EGFR Amplification and IDH Mutations in Glioblastoma Patients of the Northeast of Morocco
por: Senhaji, Nadia, et al.
Publicado: (2017)

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
por: Hwangbo, Won, et al.
Publicado: (2013)

EGFR Pathway Expression Persists in Recurrent Glioblastoma Independent of Amplification Status
por: Dhawan, Andrew, et al.
Publicado: (2023)

Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
por: Nam, Yoonhee, et al.
Publicado: (2023)

Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients
por: Bieńkowski, Michał, et al.
Publicado: (2013)

EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis
por: Talasila, Krishna M., et al.
Publicado: (2013)

The miR-183/96/182 cluster is upregulated in glioblastoma carrying EGFR amplification
por: Schneider, Björn, et al.
Publicado: (2022)

The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma
por: Kaye, Brandon, et al.
Publicado: (2023)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

Mechanisms of EGFR Resistance in Glioblastoma
por: Pan, Peter C., et al.
Publicado: (2020)

Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2021)

Correlation between EGFR Amplification and the Expression of MicroRNA-200c in Primary Glioblastoma Multiforme
por: Serna, Eva, et al.
Publicado: (2014)

Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma
por: Muñoz-Hidalgo, Lisandra, et al.
Publicado: (2019)

Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma
por: Walentynowicz, Kacper A., et al.
Publicado: (2023)

Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
por: Kim, Boyeon, et al.
Publicado: (2020)

Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2
por: Kim, Hwang-Phill, et al.
Publicado: (2009)

Next generation sequencing and molecular imaging identify EGFR mutation and amplification in a glioblastoma multiforme patient treated with an EGFR inhibitor: a case report
por: Zhou, Ke, et al.
Publicado: (2017)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Targeting immunoliposomes to EGFR-positive glioblastoma
por: Kasenda, B., et al.
Publicado: (2022)

Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
por: Kim, Seongjae, et al.
Publicado: (2023)

Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme
por: William, Doreen, et al.
Publicado: (2017)

Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma
por: Fontanilles, Maxime, et al.
Publicado: (2020)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

EGFR Gene Overexpression Retained in an Invasive Xenograft Model by Solid Orthotopic Transplantation of Human Glioblastoma Multiforme Into Nude Mice
por: Yi, Diao, et al.
Publicado: (2011)

Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification
por: Dekanić, Andrea, et al.
Publicado: (2011)

Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
por: Liam, Chong Kin, et al.
Publicado: (2023)

Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma
por: Ma, Sirui, et al.
Publicado: (2020)

Defining EGFR amplification status for clinical trial inclusion
por: French, Pim J, et al.
Publicado: (2019)

Genetic variations in EGF and EGFR and glioblastoma outcome
por: Sjöström, Sara, et al.
Publicado: (2010)

EGFR and mTOR as therapeutic targets in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_scuuhnocao4o8mct0vhebhbdsv